Journal: Oncology Research and Treatment
Extended Submission Deadline: November 30, 2024
Advancements in cellular immunotherapy have shown promising results in the treatment of both cancer and hematological malignancies. While CAR-T therapeutics are the most advanced, development continues for non-T-cell therapies including NK-cell, dendritic-cell, stem-cell, and other myeloid-derived-cell therapies. However, there are still challenges to overcome, including the need for more suitable tumor-specific targets, overcoming short duration of CAR-T cells or CAR-NK cells, reducing high production costs, and addressing high relapse rates.
We are pleased to announce a call for papers for an article collection of Oncology Research and Treatment focusing on the latest advancements in Cellular Immunotherapy. We invite original research articles, reviews, and case studies that provide new insights into this rapidly evolving field.
Please select the option “Call for Papers: Cellular Immunotherapy – State of the Art and Future Developments” when submitting your manuscript and mention this Call for Papers in your cover letter.
Oncology Research and Treatment supports Open Access publications. Corresponding authors can publish Open Access articles at no or reduced cost if they are associated with or employed by one of these universities/institutions.
Check out the Author Guidelines.